Shares of Eupraxia Pharmaceuticals have soared following the announcement that the biotech company’s Phase 2b clinical trial for EP-104IAR yielded positive results. The medication proved highly effective in relieving pain caused by knee osteoarthritis, with a meaningful improvement over the placebo shown at 12 weeks.
Positive Results from Clinical Trial
The clinical trial’s primary endpoint was clearly met, and EP-104IAR was shown to be safer than other medications commonly used for this condition. The results also suggest that EP-104IAR may be used for repeat and bilateral dosing, allowing for a versatile treatment option for patients.
Secondary Endpoints Show Statistically Significant Improvements
In addition to the primary endpoint, three of the four secondary endpoints also showed statistically significant improvements in pain relief over the placebo. While the fourth secondary endpoint didn’t meet statistical significance beyond 14 weeks, Eupraxia remains confident that EP-104IAR is still a promising choice for OA treatment.
FDA Fast-Track Designation Granted
The positive results of the clinical trial also prompted the FDA to grant fast-track designation to EP-104IAR. Eupraxia is planning to move rapidly through the late-stage development program to bring this ground-breaking product to market as soon as possible.
With Eupraxia Pharmaceuticals leading the way in osteoarthritis pain relief, patients may soon have a safe, highly effective treatment option that can address their specific needs without adverse side effects.
